Zedira is a privately held, clinical stage biopharmaceutical company specialized in transglutaminase.
Zedira’s drug candidate ZED12271
was the first transglutaminase blocker ever tested in clinical trials.
The peptidomimetic compound showed proof-of-concept in a phase 2a study in celiac disease patients. In addition, ZED1227 has a placebo-like safety profile.
For the first time, a transglutaminase is clinically validated as druggable target.
Zedira conducts several drug discovery programs targeting dysregulated human transglutaminases. The company established a pipeline of small-molecule drug candidates adapted to specific indications. We refer to the Medicine
section for comprehensive information.
Our pipeline is available on request (firstname.lastname@example.org
Specialist for Transglutaminase Martin Hils
and Ralf Pasternack
managing partners of Zedira founded the company in 2007. “Transglutaminase is our inspiration – improving health and creating value is our mission.“
Zedira is the global brand for specialty reagents for research & development as well as diagnostics in the transglutaminase field. More than 300 unique and high-quality products help accelerating transglutaminase-related research – both in academia and industry.
Scientists from academia and industry (including several of the top 15 pharmaceutical companies) benefit from Zedira’s cutting edge products and from customized services.
Zedira’s recombinant, ultra-pure and highly active microbial transglutaminases (MTG) is a unique tool to generate homogenous antibody drug conjugates (ADCs). Today, ADCs manufactured with Zedira’s MTG enter clinical trials. Find detailed information on MTG in our MTG-Handbook
Zedira products are Made in Germany by Zedira’s highly skilled professionals in an ISO9001:2015 certified facility. It is the excellent feedback from our customers which motivates us day by day to provide our high quality transglutaminase specialty reagents to researchers world wide Diagnostics
Zedira’s ISO9001:2015 certified facility enables the production of high-quality diagnostic antigens in the celiac field, including TG2, TG3, TG6 and DGPs (deamidated gliadin peptides). Moreover, Zedira’s proprietary anti-TG6-ELISA allows the detection of autoantibodies to neuronal transglutaminase (TG6), a novel marker in the field of gluten-related neurological disorders. 1
Büchold C, Hils M, Gerlach U, Weber J, Pelzer C, Heil A, Aeschlimann D, Pasternack R. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells. 2022; 11(10):1667. https://doi.org/10.3390/cells11101667